Simplex Trading, LLC Curis Inc Transaction History

Simplex Trading, LLC

  • $2.81 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 02, 2023
BUY
$0.47 - $17.22 $3,209 - $117,578
6,828 Added 38.6%
24,518 $13,000
Q3 2022

Nov 04, 2022
SELL
$0.74 - $15.01 $13,505 - $273,947
-18,251 Reduced 50.78%
17,690 $12,000
Q2 2022

Aug 03, 2022
SELL
$0.71 - $2.43 $10,564 - $36,158
-14,880 Reduced 29.28%
35,941 $35,000
Q1 2022

May 02, 2022
SELL
$2.31 - $5.13 $147,516 - $327,601
-63,860 Reduced 55.68%
50,821 $120,000
Q4 2021

Feb 23, 2022
BUY
$4.45 - $8.09 $287,870 - $523,342
64,690 Added 129.4%
114,681 $545,000
Q3 2021

Oct 28, 2021
BUY
$6.94 - $8.85 $107,361 - $136,909
15,470 Added 44.81%
49,991 $399,000
Q2 2021

Aug 12, 2021
SELL
$7.45 - $16.27 $632,005 - $1.38 Million
-84,833 Reduced 71.08%
34,521 $278,000
Q1 2021

Apr 26, 2021
BUY
$8.78 - $12.8 $574,080 - $836,928
65,385 Added 121.15%
119,354 $1.35 Million
Q4 2020

Feb 02, 2021
BUY
$1.08 - $8.2 $56,904 - $432,049
52,689 Added 4116.33%
53,969 $442,000
Q3 2020

Oct 14, 2020
BUY
$0.95 - $1.42 $1,216 - $1,817
1,280 New
1,280 $1,000
Q1 2020

Apr 29, 2020
SELL
$0.67 - $1.85 $2,960 - $8,173
-4,418 Closed
0 $0
Q4 2019

Feb 05, 2020
BUY
$1.36 - $2.44 $3,163 - $5,675
2,326 Added 111.19%
4,418 $7,000
Q3 2019

Oct 15, 2019
SELL
$1.74 - $2.83 $13,618 - $22,150
-7,827 Reduced 78.91%
2,092 $4,000
Q2 2019

Jul 26, 2019
BUY
$1.36 - $2.35 $13,489 - $23,309
9,919 New
9,919 $18,000
Q1 2019

Apr 18, 2019
SELL
$0.78 - $2.01 $2,716 - $7,000
-3,483 Closed
0 $0
Q4 2018

Jan 16, 2019
BUY
$0.62 - $2.25 $1,031 - $3,744
1,664 Added 91.48%
3,483 $2,000
Q3 2018

Oct 23, 2018
BUY
$1.38 - $1.94 $2,510 - $3,528
1,819 New
1,819 $3,000

About CURIS INC

CRIS Quotes by TradingView
  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $403M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email